#3
Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
# Summary
This news report documents the arrest of an NBA player on suspicion of driving under the influence, which lacks direct clinical relevance to cannabis medicine practice or patient care. While cannabis impairment and driving safety represent legitimate public health concerns, this article provides no medical or scientific information about cannabis pharmacology, clinical outcomes, or evidence-based guidelines. The case illustrates the real-world legal and public safety consequences of substance-related impairment but does not contribute to clinical understanding of cannabis therapeutics or risk mitigation strategies. Clinicians should remain aware that cannabis use can impair driving ability and should counsel patients about this risk, particularly those using higher-potency products or those requiring alertness for occupational safety.
“What concerns me most about high-profile DUI cases involving cannabis isn’t the arrest itself, but that we still lack standardized roadside impairment testing for THC the way we have for alcohol, which leaves law enforcement guessing and patients vulnerable to both false positives and genuine safety gaps on our roads.”
? While high-profile DUI arrests involving athletes may seem tangential to clinical practice, they underscore the real-world risks of cannabis impairment that clinicians should discuss with patients who use cannabis and drive. The pharmacokinetics of THC differ substantially from alcohol, with variable onset, duration, and subjective intoxication that may not align with impairment levels, complicating patient self-assessment of driving safety. Confounders such as concurrent alcohol or other substance use, individual cannabinoid sensitivity, and the gap between blood THC concentration and cognitive/motor impairment make risk counseling more nuanced than with traditional substances. Healthcare providers should incorporate explicit conversations about driving safety into cannabis use assessments, particularly given that many patients underestimate impairment risk or lack awareness of their own functional deficits. A practical approach is to counsel all cannabis users—especially those using high-potency products—that they should not
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
